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REVIEWPotential of Continuous Manufacturing for Liposomal
Drug ProductsRobert D. Worsham,* Vaughan Thomas, and Suzanne S. FaridOver the last several years, continuous manufacturing of pharmaceuticals
has evolved from bulk APIs and solid oral dosages into the more complex
realm of biologics. The development of continuous downstream processing
techniques has allowed biologics manufacturing to realize the benefits (e.g.,
improved economics, more consistent quality) that come with continuous
processing. If relevant processing techniques and principles are selected, the
opportunity arises to develop continuous manufacturing designs for addi-
tional pharmaceutical products including liposomal drug formulations. Lipo-
some manufacturing has some inherent aspects that make it favorable for a
continuous process. Other aspects such as formulation refinement, materials
of construction, and aseptic processing need development, but present an
achievable challenge. This paper reviews the current state of continuous
manufacturing technology applicable to liposomal drug product manufactur-
ing and an assessment of the challenges and potential of this application.1. Introduction
Continuous manufacturing is a processing concept whereby raw
materials constantly ﬂow into a process and intermediates or
ﬁnal product constantly ﬂow out. This concept has a long history
in many non-pharmaceutical industries and has recently been
adopted in some types of pharmaceutical processes such as the
synthesis of active pharmaceutical ingredients (API) and
generation of solid oral dosage forms (tablets, etc.).[1,2] The
potential beneﬁts of implementing such a concept include
economic advantages (lower capital expenditures, smaller facility
footprint, lower overall cost of goods [COG]), as well as improved
consistency and quality of product.[1,2] As success and acceptanceR. D. Worsham
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into more complex aspects and types of
pharmaceutical manufacturing.
In recent history, continuous
manufacturing has progressed into the
production of biologics. The manufacture
of biologics has continued to develop the
requirements and aspects to consider
surrounding operating upstream and
downstream unit operations in a continu-
ous fashion such as cell culture, chroma-
tography, viral inactivation, and tangential
ﬂow ﬁltration (TFF) as well as integrated
continuous upstream and downstream
processes.[3–14] For continuous perfusion
cell culture, the biologics sector has moved
from internal spin-ﬁlters to external reten-
tion devices such as alternating tangential
ﬂow (ATF) or TFF systems for media
exchange.[3,13,14] TFF systems support con-
tinuous ﬁltration by clearing the mem-brane surface with tangential ﬂuid ﬂow while ATF uses a cyclical
backﬂush. Single pass tangential ﬂow ﬁltration (SPTFF)[2] has
been evaluated for cell culture harvest concentration and for
protein concentration allowing this process step to happen in a
continuous fashion instead of the batch mode required by
traditional TFF.[15–19] TFF concentrates product through multi-
ple passes of a recirculating loop while SPTFF concentrates in an
inline fashion with a single pass through multiple TFF cassettes
in series. SPTFF enables product to be continuously fed to the
next unit operation or process step with the additional beneﬁt of
lower system hold-up volumes. These efforts towards continu-
ous ﬁltration operations are of particular interest when
considering lessons learnt that may translate to applications
in liposomal drug product formulations. Other aspects for
commercial implementation of continuous manufacturing such
as the need for process analytical technology (PAT) and the
potential advantages provided by single-use componentry have
been explored. The consensus is that PATaround critical process
measurements is a requirement for continuous processing as
this replaces the testing at intermediate stages in a batch process,
but often speciﬁcs of implementation are left to the end
user.[20,21] The implementation of single-use technology pro-
vides the same conceptual beneﬁts as it would for a batch
process, but increased in magnitude as more product is
generated per single-use item. The evaluation of these
methods/aspects have led to the conclusion that implementing
continuous manufacturing in biologics can provide potentially
similar advantages as shown in the processing of more
conventional pharmaceutical products.[17,22–24]nal Published by Wiley-VCH Verlag GmbH & Co. KGaA
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Liposomal Drug Product
Continuousmanufacturinghasbeendeﬁned inmanyways. Some
feel that the termshouldonlyapply toprocessescapableof running
24haday, 7 days aweek, and50weeksper year.[27]Others state that
the term should also include restrictions around intermediate
surge vessels or processing breaks between API and drug
product.[28] In many ways, terms such as continuous, semi-
continuous, or others are irrelevant. Each process and product
should be individually assessed to determine which concepts of
continuous manufacturing are beneﬁcial and which are not.
Converting to continuous manufacturing is not always practical
and should only be implemented after thorough evaluation.[29]
With respect to liposomal drug product manufacturing, it will
be assumed here that the end-product is a reformulation of a
compendial API and, therefore, the API is available from many
sources on a more cost-effective basis when compared to the
complexity associated with combining drug substance and drug
product manufacturing into the same process. The focus here
will be on outlining the manufacturing processes involved in
preparation of liposome formulations and how implementing
continuous manufacturing can be achieved and provide beneﬁt
to the liposomal drug products.3. Liposomal Manufacturing
Liposomeswereﬁrstdiscovered in theearly-1960s.Since thattime,a
number of strategies have been demonstrated for their manufac-
ture.[30,31] Until recently, the application of liposomal products in
pharmaceutical development has suffered from a lack of reliable
manufacturing methods with sufﬁcient throughput to enable
commercial scale-up (Table 1). Generally, strategies for liposome
synthesis focus on addressing and optimizing one or several of
the key driving forces of vesicle assembly including the component
solubilities, concentrations, and process thermodynamic parame-
ters (i.e., temperature, pressure, etc.).[30,31] Manufacture methods
canbe designed toﬁne-tune liposomeswith various properties and,
in doing so, can lend both advantages and disadvantages amenable
to large-scale processing. In addition, selection of the manufactur-
ing method often depends on the end product requirements for
clinicallyefﬁcacy including liposomesizeandsizedistribution, lipid
composition, and the drug release characteristics, together, which
dictate the pharmacokinetic demonstration of adsorption, distribu-
tion, metabolism, and elimination (ADME).Biotechnol. J. 2018, 1700740 1700740 (2 of 8) © 2018 TheThe most basic and earliest methods for liposome formation
began with multistep synthetic strategies involving the rehydra-
tion of thin phospholipid ﬁlms in aqueous media which resulted
in the spontaneous formation of lipid structures of varying sizes,
shapes, and lamella.[32–34] For uniform product generation, these
suspensions required post-formation mechanical size manipu-
lations strategies.[35,36] The combination of these methods,
although effective and well-understood, have been proven to be
inconvenient for large-scale manufacture. More recently, efforts
have been dedicated towards investigating the possibility for
single-step scalable techniques that involve programmable
online ﬂow-based strategies to arrive at the controlled precipita-
tion and subsequent self-assembly of phospholipids into
uniform structures, which is ideal for processing in a regulated
pharmaceutical environment.[37]
Themost successful examples of scaledmethods for liposome
manufacture to date have followed the principles of alcohol
injection (Figure 1A) or crossﬂow techniques (Figure 1B),
wherein dissolved lipids are precipitated from an organic solvent
into an aqueous solution (anti-solvent) by means of reciprocal
diffusion of the alcohol and aqueous phases.[38–42] A change in
the local solubility of the lipids during this process ultimately
leads to the spontaneous formation of liposomes thatAuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
Table 1. Liposome formation methods.
Method Mechanism Suitability for continuous manufacturing
Bangham[32–34] Rehydration of thin lipid film Not practical means of continuous dehydration/rehydration steps
Sonication method[65] Sonication of an aqueous lipid suspension Requires small scale batch operation for sonication to be practical
Reverse phase
evaporation[45,66]
Aqueous phase added to organic phase and evaporated to
form liposomes
Overly complex to regulate continuous solvent evaporation, sterile boundary
hard to establish
Detergent depletion[67,68] Liposomes formed through detergent lipid interaction Slow process with difficult to establish sterile boundary, detergent use
general disadvantageous
Microfluidic channel[69] Intersection of lipid/API solutions in micro-channels Very small scale, not a practical manufacturing process with existing
technology
High pressure
homogenization[35,36]
Liposome formation through high pressure mixing Very high pressures required, difficult to sterilize equipment
Heating method[30,70,71] Heating of a lipid aqueous/glycerol solution to form
liposomes
Hydration step and high temperatures make continuous production
impractical
Supercritical fluid
methods[45–50]
Use of supercritical fluids as solvent for lipids instead of
organic solvents
High pressures required for feed vessels make resupply/continuous
operation impractical
Dense Gas methods[45,50,51] Use of dense gas as solvent for lipids instead of organic
solvents
High pressures required for feed vessels make resupply/continuous
operation impractical
Ethanol/ether
injection[38,46,72,73]
Precipitation of liposome from organic phase into aqueous Simple process with inherently continuous liposome formation step, very
suitable
Crossflow method[37,39–42] In-line Precipitation of liposome from organic phase into
aqueous
Simple process with inherently continuous liposome formation step, very
suitable
www.advancedsciencenews.com www.biotechnology-journal.comencapsulate a small volume of the aqueous solution. Depending
on the chemical nature of the API, it can be encapsulated in the
aqueous core or embedded in the lipid bilayer. The critical
parameters for the formation of liposomes by this method are
residence time and geometry of the mixing/intersection of
organic-solvated lipid and the antisolvent which are dictated by
programmed ﬂow conditions. After liposome formation, the
mixture containing undesired organic solvent and unencapsu-
lated API can then be reﬁned to the desired formulation strength
and composition using TFF or similar methods.[39,43,44]
All of the aforementioned production methods were designed
to operate as a batch process, but the injection and crossﬂow
methods are based on a liposome formation step which isFigure 1. Liposomal Drug Product Manufacturing Process FlowDiagrams B
directly fed into the central vessel. B) CrossflowMethod: Solvent/anti-solvent
step buffer exchange diafiltration and concentration steps.
Biotechnol. J. 2018, 1700740 1700740 (3 of 8) © 2018 Thecontinuous in its natural mechanism (Figure 1). So long as each
feed stream is continuously fed, liposomes will be continuously
generated. It should be noted that the supercritical ﬂuid and
dense gas methods use their namesakes as the solvent for the
lipid solution while the injection and crossﬂow methods use
organic solvents. While similar in principle, supercritical and
dense gas feed solutions require high pressure that would be
difﬁcult adapt to a continuous design.[45–51] Injection and
crossﬂowmethods, which are formulated under close to ambient
conditions, present the most practical methods to adapt to
continuous operation. (See Table 1 for comments on suitability
for continuous manufacturing for each method.) With continu-
ous formulation of the feed solutions, the liposome formationatch Design. A) Ethanol/Ether InjectionMethod: Lipid/Solvent solution is
mix in-line at an intersection point. A,B) Formulations are refined in multi-
Authors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
www.advancedsciencenews.com www.biotechnology-journal.comstep canproceed indeﬁnitely. By adding continuous steps, similar to
those explored inbiologicsprocessing,which support reﬁnement of
the drug product to the desired end formulation, continuous
manufacturing of liposomal drug products is a feasible concept.4. Challenges for Continuous Liposome
Production
While the central aspect (liposome formation) of liposomal drug
product manufacturing is conducive to continuous manufactur-
ing, there are special nuances in the areas of formulation
reﬁnement, materials of construction, and sterility assurance
that need to be addressed for adaptation to a regulated
pharmaceutical environment.4.1. Formulation Refinement
The unit operations downstream of liposome formation are used
to reﬁne the drug product formulation to the desired
speciﬁcation. Frequently, unit operations such as TFF are used
to remove undesired elements, such as non-encapsulated API or
organic solvent, and concentrate the drug product to a ﬁnal
desired strength. In this case, the retentate contains the drug
product and the permeate acts as a waste stream. This is not
dissimilar from downstream unit operations in biologics
manufacturing.[52] TFF for the buffer exchange and concentra-
tion in liposomal drug product manufacturing would need to be
properly balanced to support continuous operation. A batch
mode design for this operation would entail a TFF step where the
liposome-containing retentate is returned to the central vessel
and the permeate/waste stream is made up with a feed of fresh
buffer (constant-weight diaﬁltration), facilitating the buffer
exchange. Once buffer exchange is complete, the product is
concentrated to the desired strength by ceasing buffer addition
(Figure 1). A continuous design would allow for continuous
buffer exchange and a concurrent concentration step. Arrange-
ments such as these are not unfamiliar in the world of biologics,
but unique aspects of liposomes would need to be considered
and experimentally tested for such an operation.[52] Depending
on the composition of the incoming feeds and speciﬁcation of
the desired end formulation, this could be facilitated by various
arrangements. A single vessel buffer exchange TFF system with
single stage concurrent concentrating SPTFF serves as the base
case for a continuous design (Figure 2A). If steady state
diaﬁltration or single pass concentration are not able to achieve
the required rate of buffer exchange or concentration with a
single stage, additional stages may be added (Figure 2B,C).
Additionally, more compact and elegant designs for continuous
buffer exchange, such as the Cadence1 In-line Diaﬁltration
Module (ILDF), are becoming available and should be
explored.[53] An ILDF design concluding with SPTFF would
eliminate the need for multiple vessels to support continuous
buffer exchange (Figure 2D).
SPTFF is an additional unknown for liposomal formulations,
but data has been generated for use of SPTFF for concentration
of cell culture harvest[15] or for protein concentration.[16] It
cannot be assumed that liposomes will behave the same as cellsBiotechnol. J. 2018, 1700740 1700740 (4 of 8) © 2018 Theor protein, but similar to cell suspensions and protein solutions,
liposome formulations increase in viscosity exponentially during
concentration. Since ﬁnal concentration speciﬁcations often
have a narrow tolerance, a high level of control and accuracy
would be required for such as operation. This raises and re-
enforces another canonical requirement of continuous
manufacturing, process analytical technology (PAT).
During manufacturing of liposomal formulations, there is
allowable and expected variability in capture efﬁciency of the
active ingredient. In a batch process, this is compensated for by
ofﬂine in-process measurement of active ingredient concentra-
tion prior to the concentration step. While basic measurements
such as ﬂow rates, mass, and density provide a level of control
and are easily implemented in a continuous operation, a greater
level of assurance would be provided by a real-time concentration
measurement such as in-line HPLC.[20,21]
In-line HPLC methods are available, but would require
signiﬁcant development to overcome assay requirements such as
lysing of liposomes to determine concentration, rendering it a
destructive test method. Given the feedback delay can be
overcome by the consistency of the other process controls, Rapid
HPLC, which reduces off-line testing time from 60 to 4min is a
more likely candidate.[54] Other in-line measurements, such as
particle size, may be applicable, given they can be correlated to
concentration.4.2. Materials of Construction
Many of the beneﬁts of continuously manufacturing biologics
are leveraged from the incorporation of single-use systems and
componentry.[14,22,23,55] This eliminates the need for expensive
capital equipment, simpliﬁes cleaning, and sanitization/sterili-
zation, and can provide additional ﬂexibility for multi-product
operations. However, with liposome manufacturing, single-use
componentry presents several issues. Since the manufacturing
of liposomes requires the use of organic solvents, use of single-
use components such as tubing and bags, can present issues
around extractables/leachables.[56,57] Additionally, if single-use
components are pre-sterilized through gamma-irradiation, there
can be issues with free-radical generation and incorporation into
drug product. Ultimately, these can cause degradation of some
liposome components and/or a need for signiﬁcant characteri-
zation of previously undetected impurities in the ﬁnal
product.[58] Another issue with single-use componentry is the
risk in their ability to maintain a sterile boundary, which leads to
perhaps the most speciﬁc nuance of liposome manufacturing:
aseptic processing.4.3. Sterility Assurance
Commercial scale manufacturing of liposomes, in the vast
majority of cases, will require aseptic processing. This is due to
liposomes typically having a particle size greater than 0.2 μm
(unable to be terminally sterile ﬁltered) and their instability in
the presence of excessive heat, aggressive chemicals, or radiation
(i.e., autoclave, vaporized hydrogen peroxide (VHP), e-beam,
gamma).[59,60] With aseptic processing comes the need toAuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
Figure 2. Proposed novel process designs for continuous liposome drug product manufacturing. A) Single tank buffer exchange TFF and single stage
concurrent concentrating SPTFF, B) Continuous multistage (multi-vessel) buffer exchange TFF and single stage concurrent concentrating SPTFF,
C) Single tank buffer exchange TFF and multistage concurrent concentrating SPTFF, D) Multistage buffer exchange (ILDF) with concurrent
concentrating SPTFF.
www.advancedsciencenews.com www.biotechnology-journal.comestablish and defend a sterile boundary around the process. Use
of single-use componentry can increase the risk to the integrity
of that boundary as bags and tubing assemblies can have a
higher probability of leaks (especially if custom) than more
robust reusable systems such as stainless steel.[61] Additionally,
extended use of ﬂexible tubing in pumping systems can lead to
spalling and breaches as well.[62]
Beyond building in sterility assurance through designing a
durable integral boundary, the ability to maintain an aseptic
process must be demonstrated through simulations and
validations. Assuming the process is set up using pre-sterilized
componentry and/or steam-in-place (SIP) equipment, any feed
solutions (API containing aqueous solution, lipid containing
organic solution, or buffer) must enter the system through
sterilizing ﬁlters containing a pore size of typically 0.2 μmor less.
The capability (ability of the ﬁlter to remove given concentrations
of organism) and duration (time of use before grow-through of
an organism compromises the ﬁlter) of the sterile ﬁltration step
must be validated. For a continuous design, the duration is most
concerning as the general rule of thumb for use of a sterile ﬁlter
is less than four hours. Overcoming this would require either
massively redundant ﬁltration designs or sequential use of
parallel ﬁltration pathways. Sequential use of parallel pathways is
a more viable solution since multiple redundant pathways would
cause signiﬁcant pressure drop issues. (Note: Most regulatory
authorities require redundant ﬁltration containing two ﬁlters as
standard practice).
The requirement of aseptic process validation or growth
media simulations further builds on the foundation of sterility
assurance measures such as pre-sterilized componentry, SIP,Biotechnol. J. 2018, 1700740 1700740 (5 of 8) © 2018 Theand sterile ﬁltration validation. Aseptic process validation
involves processing growth media in place of feed solutions
and product to further establish the ability to maintain an aseptic
process. These simulations should encompass the anticipated
duration of the continuous operation, which causes the re-
visitation of the continuous manufacturing deﬁnition. Ulti-
mately, simulating a multiple month process is not practical
from an operational standpoint. Simulations compete with
production and the risk to the sterile boundary increases directly
with duration of the process. The risk of growth media
simulation failure should be considered when determining
the duration of a continuous design. Conversely, FDA guidance
views a continuous operation as advantageous due to the
reduction of start-up and shut-down operations, where most
breaches occur, as compared to quantity of product produced.[63]
Ultimately, there is a risk/beneﬁt inﬂection point for each
process that should be determined.
Another consideration is the sterility sampling plan of the
bulk and/or ﬁlled ﬁnal product.[64] There is no PAT for
microbiology on the horizon, so sterility is assured through
the design and validations mentioned above, coupled with a
statistically sound sampling plan. For a batch process, a single
bulk sample is taken to assure sterility prior to proceeding with
ﬁlling. If continuous ﬁlling is integrated into the process, the
bulk will be continuously ﬂowing to the ﬁlling operation,
preventing a representative bulk sample from being taken. This
could be compensated for by taking additional samples during
the ﬁlling operation to represent both real-time bulk and ﬁlled
units. At present, the sterility assurance requirement and lack of
microbiology PAT prevent real-time release as individual unitsAuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
Figure 3. Batch vs. Continuous processing steps/times for a liposomal drug product.
www.advancedsciencenews.com www.biotechnology-journal.comcould not be released without passing microbiological results
from all bulk and all ﬁnal product samples. This is another
element to the risk/beneﬁt proﬁle that should be considered.5. Assessment of Benefits
Based on the above assumption of a feasible continuous
operation for themanufacture of liposomal formulations, a basic
case study can be performed. For the purposes of the case study,
the following options shall be compared: 1) a batch process
design producing 2500 ﬁlled units from a 1 h liposome
formation step with supporting batch process steps and 2) a
continuous process design allowing for a 24 h liposome
formation step with concurrent continuous unit operations.
The batch process is based on a real-world example used for early
phase clinical production (i.e., a 25 L bulk formulation with
10mL ﬁlls). It is assumed that the batch and continuous designs
are using similar scale equipment with similar processing rates
(i.e., a ﬁlling speed of 1250 units h1). A summary of the unit
operations and processing times is in Figure 3.
The batch process is able to produce 2500 ﬁlled units in 20 h of
total processing time including preparation (assembly, CIP/SIP,
etc.), or 125 units h1. The continuous process with a 24 h
liposome formation step would produce 60 000 ﬁlled units in
57 h of total process time or 1053 units h1. This translates to a
8.4-fold increase in output for the same overhead costs based on
units per hour and a 24-fold output increase for the same process
preparation costs and single-use componentry costs (sterilizing
ﬁlters, TFF cartridges). Additionally, the savings and output rate
could be further increased with increased ﬁlling speeds. This
ignores the additional capital expenses needed to achieve one of
the continuous designs previously mentioned.
Another way to compare the processes would be their ability to
fulﬁll a given production forecast. For a forecast of 1 million
units per year, the continuous design would require the 57-h
process to be run less than 1.5 times per month. For the batch
design, the 20-h process would have to be run more than onceBiotechnol. J. 2018, 1700740 1700740 (6 of 8) © 2018 Theper day, necessitating multiple lines running at a higher rate to
fulﬁll the forecast.
By converting the early phase clinical scale production line to
a continuous operation, not only are cost savings and higher
throughput achieved, but the need for scaling up the process is
alleviated, which eliminates the need for supporting process
development work and large-scale capital equipment
purchases.6. Conclusions
Continuous manufacturing is a concept that has clear beneﬁts to
many industries. Biologics manufacturing has taken the lead for
applying this concept to the pharmaceutical industry, but now its
application can be expanded to pharmaceutical liposomal drug
products. Given a process is designed with relevant unit
operations and consideration to materials of construction and
sterility assurance, liposomal drug products can reap the
economic and quality beneﬁts of continuous manufacturing.Abbreviations
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